Thermo Fisher Scientific enters its May 20 Q1 print with a notable tension: the stock trades at $459 — roughly 26% below the Street's average price target of $620 — yet analysts have spent the past month cutting those same targets sharply, signalling conviction is eroding even among bulls.
Options positioning tells a similar story. The put/call ratio has drifted modestly above its 20-day average at 1.31, a reading that is less than one standard deviation elevated and well below the year's peak of 2.27. That makes options caution real but not acute. Investors are buying protection, not panicking. The 52-week PCR low of 0.51 shows just how much sentiment has swung since the more bullish positioning seen earlier in the year.
Short interest, at 1.3% of the free float, is not telling a dramatic story in absolute terms — but the direction of travel is worth flagging. Estimated short shares have climbed roughly 31% over the past month, with the sharpest jump concentrated in the week of May 5-8, when shorts added position ahead of the earnings confirmation. Days to cover remains modest at 2.1, and borrow costs — though 44% higher week-on-week — are still cheap at just 0.41% annualised. Availability is loose, meaning the lending pool has not tightened meaningfully. This looks more like incremental hedging than conviction short-selling.
The analyst picture is where the real damage is concentrated. Every recent change has been a target cut. Wells Fargo trimmed to $615 from $675 on May 8, maintaining Overweight. Stifel, Baird, and Barclays all cut in the wake of the April 23 earnings miss, keeping Buy or Outperform ratings but lowering estimates substantially. The common thread: bulls still see significant upside at current levels — that $620 mean implies more than 35% to fair value — but the base is moving lower. The bear case centres on margin deterioration: adjusted EBIT margin has compressed roughly 830 basis points since 2021 to 22.6%, and biotech funding headwinds remain a drag on the CRO-facing parts of the business. Bull-case support rests on the Clario acquisition benefiting from biopharma outsourcing trends, and EPS growth projected at roughly 8.5% compounded over the next four years. At an EV/EBITDA of around 15.8x and a trailing P/E of 17.8x, the stock is trading well below historical norms for the franchise, which provides valuation support even as estimates come down.
The earnings history from the past two prints is difficult to ignore. The April 23 Q1 release produced a -8.6% one-day move and extended to -6.8% over five days. The prior print, in January, fell 11% on the day and roughly 11% over the five-day window. Two consecutive double-digit downside moves have recalibrated how the market prices in execution risk.
Peers have had a mixed week. RGEN fell 9.6% and CRL dropped 9% over the same period, suggesting sector-wide pressure rather than TMO-specific stress. BRKR, however, rallied 17.7%, and RVTY added 7.6% — a reminder that the group is not moving as one bloc. DHR was roughly flat at -4.8% for the week, broadly tracking TMO's own -1.6%.
T. Rowe Price added 2.5 million shares through Q1 and FMR added 2.1 million, making them the most active institutional buyers in the recent period. BlackRock added just over one million shares as of April 30. Insider activity through March and April has been exclusively on the sell side — CEO Marc Casper liquidated roughly 2,300 shares across multiple transactions in early March, and President Gianluca Pettiti sold 400 shares in late April. The trades are small relative to outstanding equity and carry low significance scores, suggesting scheduled-plan disposals rather than a directional signal. Net insider value sold over 90 days has reached approximately $7 million — not alarming, but consistent with the broader caution tone.
The key variable heading into May 20 is whether the guidance corridor narrows the gap between the current price and that rapidly-shrinking consensus target — or closes it further from below.
See the live data behind this article on ORTEX.
Open TMO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
